Cargando…

Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment

Small interfering RNA (siRNA) has increased the hope for highly-efficient treatment of gene-related diseases. However, the stable and efficient delivery of therapeutic nucleic acids is a prerequisite for the successful clinical translation of RNA interfering therapy. To achieve this, we condensed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Junyi, Tao, Anqi, Chen, Shun, Li, Xiaoming, Zhao, Yi, Yuan, Weien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069559/
https://www.ncbi.nlm.nih.gov/pubmed/27759095
http://dx.doi.org/10.1038/srep35661
_version_ 1782460959101550592
author Che, Junyi
Tao, Anqi
Chen, Shun
Li, Xiaoming
Zhao, Yi
Yuan, Weien
author_facet Che, Junyi
Tao, Anqi
Chen, Shun
Li, Xiaoming
Zhao, Yi
Yuan, Weien
author_sort Che, Junyi
collection PubMed
description Small interfering RNA (siRNA) has increased the hope for highly-efficient treatment of gene-related diseases. However, the stable and efficient delivery of therapeutic nucleic acids is a prerequisite for the successful clinical translation of RNA interfering therapy. To achieve this, we condensed the low molecular weight polyethyleneimine (PEI, Mw < 2000) with 2,6-pyridinedicarboxaldehyde (PDA) to synthesize a biologically responsive and degradable cationic polymer (abbreviated to PDAPEI) which was utilized as a gene vector for the delivery of a VEGF-A shRNA expression plasmid DNA (pDNA). The resulting electrostatic interaction between PDAPEI and pDNA led to the self-assembly of nanoscale polyplexes with suitable particle size and stable zeta potential. The PDAPEI/pDNA polyplexes demonstrated an outstanding gene transfection and silencing efficiency at 30 w/w ratio, as well as negligible cytotoxicity. Also, the designed polymer showed no stimulation to the innate immune system. Moreover, compared with PEI 25 KDa, the polyplexes accomplished comparatively better anti-angiogenesis efficacy, which resulted in the inhibition of tumor growth in subcutaneous tumor mice models. In conclusion, PDAPEI has great potential to be a gene delivery vector for cancer therapy.
format Online
Article
Text
id pubmed-5069559
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50695592016-10-26 Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment Che, Junyi Tao, Anqi Chen, Shun Li, Xiaoming Zhao, Yi Yuan, Weien Sci Rep Article Small interfering RNA (siRNA) has increased the hope for highly-efficient treatment of gene-related diseases. However, the stable and efficient delivery of therapeutic nucleic acids is a prerequisite for the successful clinical translation of RNA interfering therapy. To achieve this, we condensed the low molecular weight polyethyleneimine (PEI, Mw < 2000) with 2,6-pyridinedicarboxaldehyde (PDA) to synthesize a biologically responsive and degradable cationic polymer (abbreviated to PDAPEI) which was utilized as a gene vector for the delivery of a VEGF-A shRNA expression plasmid DNA (pDNA). The resulting electrostatic interaction between PDAPEI and pDNA led to the self-assembly of nanoscale polyplexes with suitable particle size and stable zeta potential. The PDAPEI/pDNA polyplexes demonstrated an outstanding gene transfection and silencing efficiency at 30 w/w ratio, as well as negligible cytotoxicity. Also, the designed polymer showed no stimulation to the innate immune system. Moreover, compared with PEI 25 KDa, the polyplexes accomplished comparatively better anti-angiogenesis efficacy, which resulted in the inhibition of tumor growth in subcutaneous tumor mice models. In conclusion, PDAPEI has great potential to be a gene delivery vector for cancer therapy. Nature Publishing Group 2016-10-19 /pmc/articles/PMC5069559/ /pubmed/27759095 http://dx.doi.org/10.1038/srep35661 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Che, Junyi
Tao, Anqi
Chen, Shun
Li, Xiaoming
Zhao, Yi
Yuan, Weien
Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment
title Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment
title_full Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment
title_fullStr Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment
title_full_unstemmed Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment
title_short Biologically responsive carrier-mediated anti-angiogenesis shRNA delivery for tumor treatment
title_sort biologically responsive carrier-mediated anti-angiogenesis shrna delivery for tumor treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069559/
https://www.ncbi.nlm.nih.gov/pubmed/27759095
http://dx.doi.org/10.1038/srep35661
work_keys_str_mv AT chejunyi biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment
AT taoanqi biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment
AT chenshun biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment
AT lixiaoming biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment
AT zhaoyi biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment
AT yuanweien biologicallyresponsivecarriermediatedantiangiogenesisshrnadeliveryfortumortreatment